A carregar...

Iodine‐131‐meta‐iodobenzylguanidine therapy for patients with newly diagnosed high‐risk neuroblastoma

BACKGROUND: Patients with newly diagnosed high‐risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi‐modality intensive therapy. This poor outcome necessitates the search for new therapies, such as treatment with (131)I‐meta‐iodobenzylguanidine ((131)I‐MIBG). OBJECTIVES: To assess t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cochrane Database Syst Rev
Main Authors: Kraal, Kathelijne CJM, van Dalen, Elvira C, Tytgat, Godelieve AM, Van Eck‐Smit, Berthe LF
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2017
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478145/
https://ncbi.nlm.nih.gov/pubmed/28429876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010349.pub2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!